TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01925131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study: NCT01737086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and zinc sulphate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02525523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alicaforsen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01925131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study: NCT04449692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Abdominal s.c. administration
Study: NCT01925131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04449692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Abdominal s.c. administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate (dextrose tablets)
Description: Oral administration
Study: NCT01925131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03436264

Intervention type: OTHER
Intervention: MRI
Description: fMRI

Intervention type: OTHER
Intervention: MRI
Description: fMRI
Study: NCT01925131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01948193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine
Description: 0.5 mL, Intramuscular
Study: NCT04816409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,
Study: NCT01364987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study: NCT03437187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Laparoscopic technique

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cholecystectomy
Description: Laparoscopic technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholecystectomy
Description: Laparoscopic technique
Study: NCT01044355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: 6 weeks treatment with fixed CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: 6 weeks of treatment with auto-titrating positive airway pressure
Study: NCT03206502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embrace + Alert App
Description: Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
Study: NCT01491087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTacP IPV//PRP~T combined vaccine: PENTAXIM®
Description: 0.5 mL, Intramuscular
Study: NCT01275404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls
Description: Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction
Description: Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
Study: NCT00759629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional treatment group
Description: Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment group
Description: Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
Study: NCT01978561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post dosing with NT100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post dosing with NT100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post dosing with Placebo
Study: NCT04816409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy
Description: Starting Posture~* Start and evaluate the supreme effective posture to move from(usually straight)~* Reassemble to mid plane (head/trunk)~* Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li
Study: NCT01583088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phenique nerve stimulation NeurX™ (Synapse Biomedical)
Description: phenique nerve stimulation NeurX™ (Synapse Biomedical)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham phrenic nerve stimulation
Description: sham phenic nerve stimulation
Study: NCT04396587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil(0.1μg/kg) was administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone(20μg/kg)was administered before anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone(60μg/kg) was administered before anesthesia induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: normal saline 10ml
Study: NCT00786240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
Study: NCT02441530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study: NCT03150940

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: 12 lead electrocardiogram used to demonstrate cardiac function
Study: NCT03793153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Cooling Technique
Description: Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
Study: NCT04096482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peregrine Drivable ENT Scope
Description: Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
Study: NCT03150940

Intervention type: DIAGNOSTIC_TEST
Intervention: bedside cardiac ultrasound
Description: bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
Study: NCT04124965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study: NCT04278131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS01
Description: Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
Study: NCT04486144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprietary extract of Nerium oleander
Description: This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
Study: NCT04096482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard 30° 4mm Endoscope
Description: The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
Study: NCT00576420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS VH S/D 500 s-apr, 60-seconds polymerization time
Description: FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS VH S/D 500 s-apr, 120-seconds polymerization time
Description: Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression with surgical gauze pads
Description: Treatment of the study suture line with manual compression with surgical gauze pads.
Study: NCT03050775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Ventilator Circuit
Description: active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ventilator Circuit
Description: no active heat and humidification during anesthesia
Study: NCT02616146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENG-E2 125 μg/300 μg vaginal ring
Description: Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-EE 150 μg/30 μg COC
Description: Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
Study: NCT02695160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-FIX
Description: Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-FIX
Description: Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-FIX
Description: Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
Study: NCT01696929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion.
Study: NCT01221272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: * One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: * One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ranolazine
Description: Placebo to match ranolazine administered in the same form and frequency as the active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ranolazine
Description: Placebo to match ranolazine administered in the same form and frequency as the active drug.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT MPI
Description: Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT MPI
Description: Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Treadmill stress test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Treadmill stress test
Study: NCT01340872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST10-021
Description: 30 mg capsules to be taken orally twice a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching sugar pill to be taken orally twice a day for 12 weeks
Study: NCT03521102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000mg IV
Description: 1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 0.5 mg IV
Description: 100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
Study: NCT01502332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Alveolar Recruitment
Description: Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Alveolar Recruitment
Description: Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
Study: NCT04278131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS01
Description: Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS01
Description: Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS01
Description: Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
Study: NCT03237676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured cognitive rehabilitation therapy
Description: A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
Study: NCT02013362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Study: NCT03343028

Intervention type: OTHER
Intervention: Psychotherapy
Study: NCT01660542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy with Docetaxel
Description: Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -\> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
Study: NCT03237676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-centred cognitive therapy
Description: Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review.
Study: NCT03381443

Intervention type: OTHER
Intervention: different assessments
Description: coded survey about NTS and assessment

Intervention type: OTHER
Intervention: different assessments
Description: coded survey about NTS and assessment